Therma Bright Inc. (TSX.V: THRM) (OTC: THRBF) Addressing Dermatological Needs with Premier Medical Devices
- Therma Bright’s products target the multi-billion dollar skin care device market
- Its non-invasive, pain-free skin care offerings are based on proprietary technology
- Therma Bright currently has two products on the market, plus an additional one in development
Therma Bright Inc. (TSX.V: THRM) (OTC: THRBF) concentrates on providing first-rate medical devices that address dermatological needs. At present, the company has two products on the market and one in the research and development phase. Its portfolio includes products, devices and treatments that have cosmetic and medicinal or therapeutic benefits. Based in Toronto, Ontario, Therma Bright has significant investments in intellectual property and R&D.
Therma Bright’s products target the $10.7 billion skin care device market. Moreover, regarding the overall dermatology market, as reported by MarketResearch.com (http://nnw.fm/Tf8w7), “…the US has the largest market for dermatology and is also forecast to be the leading market through 2028; GMR Data forecasts $12.3 billion in 2018 growing to $22.6 billion in 2028.” In addition, Medgadget (http://nnw.fm/aMIs4) noted that, “…the global dermatology devices market is expected to grow at a CAGR of 11.4% between 2018 and 2025.”
The foundation of Therma Bright’s non-invasive, pain-free skin care offerings is proprietary technology that has received class II medical device status from the U.S. Food and Drug Administration (“FDA”). The company’s products include the InteceptCS Cold Sore Prevention Device and the TherOZap Insect Bite Treatment Device. One focus of Therma Bright’s products, devices and treatments is providing relief of pain, itch and inflammation resulting from over 20,000 kinds of insect and marine life bites and stings.
The InterceptCS Cold Sore Prevention System provides controlled topical heat without the risk of burning the skin, and its controlled range of heat naturally prevents cold sore eruptions*. The system consists of an ergonomically designed hand-held unit and a disposable treatment activator (http://nnw.fm/cjq4J). InterceptCS is a high gross margin product. Therma Bright recently redesigned a multi-use activator for the legacy product, which launched formerly with Canada’s largest pharmacy chain and included two free single-use activators (http://nnw.fm/9M8bp).
The first-generation TherOZap Insect Bite Treatment Device received FDA approval as a class II medical device for the relief of the symptoms of pain, itch and inflammation associated with insect bites and stings. Therma Bright has been working with engineers and designers to complete a TherOZap prototype. This prototype will be tested for effectiveness against the Zika virus, as well as other mosquito-borne diseases (http://nnw.fm/HzxC0).
Furthermore, Therma Bright is focusing on designing and developing a thermal therapy pain relief device using medicinal cannabis or cannabidiol from hemp in the form of gels or creams (http://nnw.fm/kSw5V). The company recently announced that it will incorporate a 100 percent wholly owned subsidiary to hold device-related technology for the application or use of medicinal or recreational marijuana (http://nnw.fm/7bIn5).
Therma Bright is ahead of the curve as it works to build recurring revenue streams from its products while incorporating intelligent technology such as AI and IoT. With a current emphasis on marketing its products online via different social media networks, Therma Bright is steadily advancing its growth initiatives. For investors, the company offers the opportunity for return on investment from the burgeoning skin care device and dermatology markets.
For more information, visit the company’s website at www.ThermaBright.com
* Based on double blind placebo study the InterceptCS is approved for the claim “For prevention of cold sores when used within 3 hours of the onset of the prodrome” by Health Canada. The InterceptCS is not approved by the United States FDA for any claim of clinical indication, clinical efficacy and/or cure or prevention of disease.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Therma Bright’s products target the multi-billion dollar skin care device market
- Its non-invasive, pain-free skin care offerings are based on proprietary technology
- Therma Bright currently has two products on the market, plus an additional one in development
Therma Bright Inc. (TSX.V: THRM) (OTC: THRBF) concentrates on providing first-rate medical devices that address dermatological needs. At present, the company has two products on the market and one in the research and development phase. Its portfolio includes products, devices and treatments that have cosmetic and medicinal or therapeutic benefits. Based in Toronto, Ontario, Therma Bright has significant investments in intellectual property and R&D.
Therma Bright’s products target the $10.7 billion skin care device market. Moreover, regarding the overall dermatology market, as reported by MarketResearch.com (http://nnw.fm/Tf8w7), “…the US has the largest market for dermatology and is also forecast to be the leading market through 2028; GMR Data forecasts $12.3 billion in 2018 growing to $22.6 billion in 2028.” In addition, Medgadget (http://nnw.fm/aMIs4) noted that, “…the global dermatology devices market is expected to grow at a CAGR of 11.4% between 2018 and 2025.”
The foundation of Therma Bright’s non-invasive, pain-free skin care offerings is proprietary technology that has received class II medical device status from the U.S. Food and Drug Administration (“FDA”). The company’s products include the InteceptCS Cold Sore Prevention Device and the TherOZap Insect Bite Treatment Device. One focus of Therma Bright’s products, devices and treatments is providing relief of pain, itch and inflammation resulting from over 20,000 kinds of insect and marine life bites and stings.
The InterceptCS Cold Sore Prevention System provides controlled topical heat without the risk of burning the skin, and its controlled range of heat naturally prevents cold sore eruptions*. The system consists of an ergonomically designed hand-held unit and a disposable treatment activator (http://nnw.fm/cjq4J). InterceptCS is a high gross margin product. Therma Bright recently redesigned a multi-use activator for the legacy product, which launched formerly with Canada’s largest pharmacy chain and included two free single-use activators (http://nnw.fm/9M8bp).
The first-generation TherOZap Insect Bite Treatment Device received FDA approval as a class II medical device for the relief of the symptoms of pain, itch and inflammation associated with insect bites and stings. Therma Bright has been working with engineers and designers to complete a TherOZap prototype. This prototype will be tested for effectiveness against the Zika virus, as well as other mosquito-borne diseases (http://nnw.fm/HzxC0).
Furthermore, Therma Bright is focusing on designing and developing a thermal therapy pain relief device using medicinal cannabis or cannabidiol from hemp in the form of gels or creams (http://nnw.fm/kSw5V). The company recently announced that it will incorporate a 100 percent wholly owned subsidiary to hold device-related technology for the application or use of medicinal or recreational marijuana (http://nnw.fm/7bIn5).
Therma Bright is ahead of the curve as it works to build recurring revenue streams from its products while incorporating intelligent technology such as AI and IoT. With a current emphasis on marketing its products online via different social media networks, Therma Bright is steadily advancing its growth initiatives. For investors, the company offers the opportunity for return on investment from the burgeoning skin care device and dermatology markets.
For more information, visit the company’s website at www.ThermaBright.com
* Based on double blind placebo study the InterceptCS is approved for the claim “For prevention of cold sores when used within 3 hours of the onset of the prodrome” by Health Canada. The InterceptCS is not approved by the United States FDA for any claim of clinical indication, clinical efficacy and/or cure or prevention of disease.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
